Amlodipine besylate

(Norvasc®)

Norvasc®

Drug updated on 11/4/2024

Dosage FormTablet (oral: 2.5 mg, 5 mg, 10 mg)
Drug ClassCalcium channel blockers
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • For the treatment of hypertension, to lower blood pressure
  • Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions
  • For the treatment of coronary artery disease; chronic stable angina; vasospastic angina (prinzmetal's or variant angina); angiographically documented coronary artery disease in patients without heart failure or an ejection fraction < 40%.

Latest News

loading GIF

Summary
This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

  • This summary is based on the review of 11 systematic review(s)/meta-analysis(es). [1-11]
  • Perindopril/amlodipine fixed-dose combination significantly lowers blood pressure and improves blood pressure control, demonstrating superior adherence and fewer side effects compared to monotherapy and placebo in general hypertensive patients.
  • For vasospastic angina (VSA), diltiazem, nifedipine, and amlodipine effectively reduce VSA episodes; however, each presents different side effects, with diltiazem associated with atrioventricular block and nifedipine with excessive blood pressure reduction and heart rate increase.
  • In preventing atrial fibrillation (AF) recurrence in hypertensive patients, angiotensin II receptor blockers (ARBs) show superior effectiveness over calcium channel blockers (CCBs), including amlodipine.
  • In hypertensive patients with chronic kidney disease, benidipine outperforms amlodipine in improving estimated glomerular filtration rate (eGFR) and reducing urinary albumin/creatinine ratio, despite similar outcomes in blood pressure and heart rate reduction.
  • There is no population types or subgroups information available in the reviewed studies.

Product Monograph / Prescribing Information

Document TitleYearSource
Norvasc (amlodipine besylate) Prescribing Information.2023Viatris Specialty LLC, Canonsburg, PA

Systematic Reviews / Meta-Analyses

Document TitleYearSource
Single-Pill Combination Therapy of Amlodipine, Telmisartan, and Chlorthalidone in the Management of Hypertension: A Systematic Review of Randomized Controlled Trials2024Cureus
Effectiveness of perindopril/amlodipine fixed-dose combination in the treatment of hypertension: a systematic review2023Frontiers In Pharmacology
Efficacy and Safety of Azelnidipine as an Antihypertensive Compared to Amlodipine: A Systematic Review and Meta-analysis2023High Blood Pressure & Cardiovascular Prevention : The Official Journal Of The
Comparison of various calcium antagonist on vasospastic angina: a systematic review2023Open Heart
A Reappraisal of the Effects of L-type Ca(2+) Channel Blockers on Store-Operated Ca(2+) Entry and Heart Failure2023Function (Oxford, England)
Angiotensin Receptor Blocker and Calcium Channel Blocker Preventing Atrial Fibrillation Recurrence in Patients with Hypertension and Atrial Fibrillation: A Meta-analysis2021Cardiovascular Therapeutics
Berberine for the treatment of hypertension: A systematic review2021Complementary Therapies In Clinical Practice
Amlodipine Compared with Benidipine in the Management of Hypertension: A Systematic Review and Meta-Analysis2020High Blood Pressure & Cardiovascular Prevention : The Official Journal Of The
Comparative efficacy and safety of oral antihypertensive agents in pregnant women with chronic hypertension: a network metaanalysis2020American Journal Of Obstetrics And Gynecology
Economic evaluation of olmesartan/amlodipine fixed-dose combination for hypertension treatment in China2020Journal Of Medical Economics
Systematic Review with Network Meta-Analysis: Comparative Efficacy and Safety of Combination Therapy with Angiotensin II Receptor Blockers and Amlodipine in Asian Hypertensive Patients2019International Journal Of Hypertension

Clinical Practice Guidelines